Nadifloxacin

Nadifloxacin

CAT N°: 20252
Price:

From 48.00 40.80

Nadifloxacin is a fluoroquinolone antibiotic.{57958} It is active against clinical isolates of S. aureus, coagulase-negative staphylococci, P. acnes, and P. granulosum (MIC50s = 0.03, 0.06, 0.25, and 0.125 mg/L, respectively). Nadifloxacin inhibits the activities of DNA gyrase and topoisomerase IV (IC50s = 8.83 and 3.22 mg/L, respectively, for the S. aureus enzymes).{57959} Nadifloxacin (30 µg/ml) inhibits P. acnes-induced increases in the production of IFN-?, IL-1?, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs), as well as reduces P. acnes-induced increases in the production of IL-8 and IL-6 in isolated human keratinocytes.{57960} Topical application of a cream containing nadifloxacin (1%) reduces the number of skin lesion colony forming units (CFUs) in a mouse model of burn wounds infected with S. aureus or P. acnes.{57959} Formulations containing nadifloxacin have been used in the treatment of acne vulgaris.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 9-fluoro-6,7-dihydro-8-(4-hydroxy-1-piperidinyl)-5-methyl-1-oxo-1H,5H-benzo[ij]quinolizine-2-carboxylic acid
  • Correlated keywords
    • 81962-84-7 OPC7251 nadixa jinofloxacin fluoroquinolone topical Gram-positive bacteria Gram-negative staphylococcus propionibacterium anti-biotic Propionibacteriaceae interleukin IFN? IL1? IL12p70 IL-12 IL12 p70 IL8 IL6
  • Product Overview:
    Nadifloxacin is a fluoroquinolone antibiotic.{57958} It is active against clinical isolates of S. aureus, coagulase-negative staphylococci, P. acnes, and P. granulosum (MIC50s = 0.03, 0.06, 0.25, and 0.125 mg/L, respectively). Nadifloxacin inhibits the activities of DNA gyrase and topoisomerase IV (IC50s = 8.83 and 3.22 mg/L, respectively, for the S. aureus enzymes).{57959} Nadifloxacin (30 µg/ml) inhibits P. acnes-induced increases in the production of IFN-?, IL-1?, and IL-12p70 in human peripheral blood mononuclear cells (PBMCs), as well as reduces P. acnes-induced increases in the production of IL-8 and IL-6 in isolated human keratinocytes.{57960} Topical application of a cream containing nadifloxacin (1%) reduces the number of skin lesion colony forming units (CFUs) in a mouse model of burn wounds infected with S. aureus or P. acnes.{57959} Formulations containing nadifloxacin have been used in the treatment of acne vulgaris.

We also advise you